Skip to content 
Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, develops resveratrol platform products for the treatment of neuroinflammation. The company develops JNS101, which is in Phase II trial for the treatment of Friedreich's Ataxia, a rare inherited disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS108 that is in Phase II trial for treating mild cognitive impairment/early Alzheimer's disease. It is also involved in the development of JNS102, which is in Phase II trial for the treatment of mucopolysaccharidosis type 1; and JNS107 that is in Phase II trial for treating mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes syndrome. In addition, the company develops JNS115, which is in Phase IIa trial for the treatment of Parkinson's disease. It has a strategic partnership with Zina Biopharmaceuticals, LLC to advance Phase 2a clinical trial to evaluate the safety, tolerability, and pharmacokinetics of Resveratrol (JOTROLTM) in individuals with Parkinson's disease; and with Aquanova AG to develop a series of consumer-focused nutritional products targeting longevity, aging, and healthspan. The company was formerly known as Jupiter Orphan Therapeutics, Inc. and changed its name to Jupiter Neurosciences, Inc. in August 2021. Jupiter Neurosciences, Inc. was incorporated in 2016 and is headquartered in Jupiter, Florida. more
| Time Frame | JUNS | Sector | S&P500 |
|---|---|---|---|
| 1-Week Return | -8.98% | 1.51% | -1.5% |
| 1-Month Return | -37.8% | 1.46% | 0.6% |
| 3-Month Return | -55.92% | 3.94% | 2.43% |
| 6-Month Return | -54.85% | 16.03% | 6.01% |
| 1-Year Return | -33.2% | 9.1% | 11.48% |
| 3-Year Return | -89.8% | 19.46% | 67.52% |
| Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | 5YR TREND | |
|---|---|---|---|---|---|---|
| Total Revenue | 1.13M | 638.04K | 233.28K | - | - | [{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":56.65,"profit":true},{"date":"2022-12-31","value":20.71,"profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}] |
| Cost of Revenue | - | - | - | - | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}] |
| Gross Profit | 1.13M | 638.04K | 233.28K | - | - | [{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":56.65,"profit":true},{"date":"2022-12-31","value":20.71,"profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}] |
| Gross Margin | 100.00% | 100.00% | 100.00% | - | - | [{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}] |
| Operating Expenses | 2.98M | 4.55M | 3.67M | 3.87M | 3.09M | [{"date":"2020-12-31","value":65.52,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":80.65,"profit":true},{"date":"2023-12-31","value":85.16,"profit":true},{"date":"2024-12-31","value":68.01,"profit":true}] |
| Operating Income | (1.85M) | (3.91M) | (3.43M) | (3.87M) | (3.09M) | [{"date":"2020-12-31","value":-185159400,"profit":false},{"date":"2021-12-31","value":-390709700,"profit":false},{"date":"2022-12-31","value":-343244700,"profit":false},{"date":"2023-12-31","value":-387077100,"profit":false},{"date":"2024-12-31","value":-309128200,"profit":false}] |
| Total Non-Operating Income/Expense | 183.40K | (407.02K) | (2.27M) | (1.13M) | 408.85K | [{"date":"2020-12-31","value":44.86,"profit":true},{"date":"2021-12-31","value":-99.55,"profit":false},{"date":"2022-12-31","value":-554.09,"profit":false},{"date":"2023-12-31","value":-276.67,"profit":false},{"date":"2024-12-31","value":100,"profit":true}] |
| Pre-Tax Income | (1.65M) | (4.20M) | (4.96M) | (4.78M) | (2.44M) | [{"date":"2020-12-31","value":-165469900,"profit":false},{"date":"2021-12-31","value":-420025900,"profit":false},{"date":"2022-12-31","value":-495758000,"profit":false},{"date":"2023-12-31","value":-478368900,"profit":false},{"date":"2024-12-31","value":-243962500,"profit":false}] |
| Income Taxes | - | 179.17K | - | - | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}] |
| Income After Taxes | - | (4.38M) | - | - | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":-437942700,"profit":false},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}] |
| Income From Continuous Operations | (1.65M) | (4.20M) | (4.96M) | (4.78M) | (2.44M) | [{"date":"2020-12-31","value":-165469900,"profit":false},{"date":"2021-12-31","value":-420025900,"profit":false},{"date":"2022-12-31","value":-495758000,"profit":false},{"date":"2023-12-31","value":-478368900,"profit":false},{"date":"2024-12-31","value":-243962500,"profit":false}] |
| Income From Discontinued Operations | - | - | - | - | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}] |
| Net Income | (1.65M) | (4.38M) | (4.96M) | (4.78M) | (2.44M) | [{"date":"2020-12-31","value":-165469900,"profit":false},{"date":"2021-12-31","value":-437942700,"profit":false},{"date":"2022-12-31","value":-495758000,"profit":false},{"date":"2023-12-31","value":-478368900,"profit":false},{"date":"2024-12-31","value":-243962500,"profit":false}] |
| EPS (Diluted) | - | (0.10) | - | - | (0.07) | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":-10,"profit":false},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":-7,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
| JUNS | |
|---|---|
| Cash Ratio | 0.29 |
| Current Ratio | 0.65 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
| JUNS | |
|---|---|
| ROA (LTM) | -354.94% |
| ROE (LTM) | 0.00% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
| JUNS | |
|---|---|
| Debt Ratio Lower is generally better. Negative is bad. | 0.98 |
| Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.02 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
| JUNS | |
|---|---|
| Trailing PE | NM |
| Forward PE | 9.52 |
| P/S (TTM) | 0.00 |
| P/B | 342.48 |
| Price/FCF | NM |
| EV/R | 0.00 |
| EV/Ebitda | NM |
Jupiter Neurosciences, Inc. Common Stock (JUNS) share price today is $0.5598
Yes, Indians can buy shares of Jupiter Neurosciences, Inc. Common Stock (JUNS) on Vested. To buy
Yes, you can purchase fractional shares of Jupiter Neurosciences, Inc. Common Stock (JUNS) via the Vested app. You can start investing in Jupiter Neurosciences, Inc. Common Stock (JUNS) with a minimum investment of $1.
You can invest in shares of Jupiter Neurosciences, Inc. Common Stock (JUNS) via Vested in three simple steps:
The 52-week high price of Jupiter Neurosciences, Inc. Common Stock (JUNS) is $3.33. The 52-week low price of Jupiter Neurosciences, Inc. Common Stock (JUNS) is $0.48.
The price-to-earnings (P/E) ratio of Jupiter Neurosciences, Inc. Common Stock (JUNS) is
The price-to-book (P/B) ratio of Jupiter Neurosciences, Inc. Common Stock (JUNS) is 342.48
The dividend yield of Jupiter Neurosciences, Inc. Common Stock (JUNS) is 0.00%
The market capitalization of Jupiter Neurosciences, Inc. Common Stock (JUNS) is $19.89M
The stock symbol (or ticker) of Jupiter Neurosciences, Inc. Common Stock is JUNS
Consider the share price of Jupiter Neurosciences, Inc. Common Stock as a long-term story and not a daily point list. The price represents a movement of the stock in both good and bad times when looked at over many years. This assists the investors to know whether Jupiter Neurosciences, Inc. Common Stock has succeeded to expand steadily and overcome market declines. With this price movement observed and the way the business is progressing, it is easier to make a decision whether the stock is worth having in the long term or not.
When investing in Jupiter Neurosciences, Inc. Common Stock shares, you are not based in India then your investment is not just based on the stock price. It is also determined by the currency movement of the dollar in relation to the rupee. When you have an appreciation of the Jupiter Neurosciences, Inc. Common Stock stock and the dollar appreciation is also the same, you gain more in terms of rupees. When the rupee appreciated, it will lower your profits. This currency flow is a silent cause of great contribution to your ultimate returns over many years.
Rather than merely checking the share price of Jupiter Neurosciences, Inc. Common Stock and comparing it with that of other stocks in the same sector, one can check how robust the business is. Investors tend to compare such aspects as profits, cash generation, and the stability of the revenues of the company. This means that Jupiter Neurosciences, Inc. Common Stock stock in most cases does not react in the same manner as other companies in the sector due to its brand and services revenue.
Link copied 
